Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Melissa Dillmon (NPI 1790845071)

Field	Value
Entity Type	Individual
Organization	Melissa Dillmon
Address	255 W 5th St Sw
City	Rome
State	GA
ZIP	30165
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 9, 2006

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

Practice profile and service mix: MELISSA DILLMON is a Hematology & Oncology Physician with an NPI enumerated on 2006-12-09 (~20 years ago), and her Medicare billing profile is dominated by infusion and biologic drug administration codes (for example J9271, J0897, J1568) alongside chemotherapy administration add‑ons such as 96413 and 96417. The top procedure and drug mix—large volumes of monoclonal antibody injections and standard chemotherapy administration codes—is consistent with an infusion-centered oncology practice that delivers in‑office biologic therapies and supportive oncology care.

Revenue concentration in Medicare: This provider has $2M in total Medicare revenue and the top 3 Medicare codes by revenue (J9271, J0897, J1568) account for 84.5% of that Medicare revenue, indicating a very concentrated revenue base tied to a small set of high‑value drug administrations. J9271 alone represents $1M (54.2% of Medicare revenue) while J0897 and J1568 together contribute a further large share, underscoring dependence on a few biologic agents.

Payer mix: The provider is effectively single‑payer in the record set — Medicare represents the entire reported public‑payer revenue ($2M) and there is no Medicaid billing on file, so Medicaid does not appear to be a source of revenue in state datasets. This lack of Medicaid volume means analysis of Medicaid positioning or state‑level payer diversification is not possible from the available data.

Competitive standing on denosumab (J0897): The provider’s J0897 volume is an outlier nationally—25.1K claims generating $452.5K (23.4% of Medicare revenue) and ranked #157 of 10057 providers nationally (98th percentile) and labeled an "extreme outlier, far above typical national volume for this code." This suggests an unusually large role in administering denosumab relative to peers, which may reflect a high concentration of patients receiving bone‑directed therapy or local referral patterns for this specific agent.

Competitive standing on pembrolizumab (J9271) and trastuzumab biosimilar (Q5116): J9271 accounts for $1M (54.2% of Medicare revenue) and ranks #237 of 1841 providers nationally (87th percentile) where volume is described as "typical, unremarkable" for the code, indicating solid but not dominant pembrolizumab use relative to the national oncology provider pool. Conversely, Q5116 (biosimilar trastuzumab) is notably above typical national volume—3K claims generating $63.7K (3.3% of Medicare revenue) and ranking #3 of 34 providers nationally (94th percentile)—pointing to above‑average use of this trastuzumab biosimilar among the small national cohort that bills it.

Operational implications from Procedure/E&M mix: While drug administrations dominate revenue, the practice also bills routine oncology E/M and infusion codes (for example 99214: 563 claims, $46.7K, 2.4% of Medicare revenue; 96413: 481 claims, $42.3K, 2.2% of Medicare revenue; 96372: 489 claims, $4.9K, 0.3% of Medicare revenue). These non‑drug codes show that the practice provides standard patient evaluation and multiple infusion services in support of the high drug utilization, consistent with outpatient oncology practice workflows where drug reimbursement drives revenue and E/M + administration codes generate supplemental revenue.

Notable statistical signals beyond the top two drugs: Several administration and supportive care codes appear above typical national volumes—96372 is ranked in the 97th percentile (489 claims, $4.9K), and Q5116 is in the 94th percentile—whereas many routine lab and E/M codes sit in typical percentile ranges. These elevated percentiles for specific administration codes reinforce the interpretation that this provider’s operation is highly procedural and infusion‑oriented, with certain supportive injections and biosimilars used at higher rates than peers.

Risk and strategic considerations for payers: Given the heavy revenue concentration in a small number of biologic drug codes (top 3 = 84.5% of Medicare revenue) and the provider’s status as an outlier on J0897, payers evaluating network strategy or utilization management should focus on drug procurement practices, site‑of‑care cost differentials, and clinical pathways for bone‑targeted therapy and immunotherapy. The absence of Medicaid billing simplifies public‑payer oversight to Medicare only, but also indicates limited exposure to state Medicaid populations in this provider’s billing footprint.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

58 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	24,400	$40	$1M
J0897	Injection, denosumab, 1 mg	25,140	$20	$452.5K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,920	$30	$133.3K
Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg	3,030	$20	$63.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	560	$80	$46.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$90	$42.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	470	$70	$31.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	240	$60	$14.3K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	1,510	$10	$12.1K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	1,000	$10	$10K

Showing 1–10 of 58

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 58 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Melissa Dillmon — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

58 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	40	15,200	$40	$767.3K
J1568	1	10	3,700	$30	$113.3K
J0897	5	290	2,460	$20	$90.2K
Q5116	1	10	3,030	$20	$63.9K
J2506	5	10	460	$80	$34.1K
96413	18	160	170	$90	$20.3K
J3490	31	50	50	$320	$19.8K
99214	1,242	13,640	120	$80	$17.8K
99233	3,302	3,880	90	$90	$13.9K
J0185	10	20	7,150	$1	$13.9K

Showing 1–10 of 58

Related Providers

Other providers that share a Tax Identification Number (TIN) with Melissa Dillmon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dimple Modi	GA	Retina Specialist (Ophthalmology) Physician	$2.7M	$0
Gregory Harris	GA	Hematology & Oncology Physician	$2M	$0
Dilawar Khan	GA	Hematology & Oncology Physician	$1.9M	$0
Jeffrey Peller	GA	Rheumatology Physician	$1.1M	$0
Harbin Clinic, LLC	GA	Ambulatory Surgical Clinic/Center	$754.6K	$0
Matthew Mumber	GA	Radiation Oncology Physician	$636.9K	$0
Rahul Garg	GA	Cardiovascular Disease Physician	$605K	$0
John Abdou	GA	Radiation Oncology Physician	$601.9K	$0
Charles Baggett	GA	Cardiovascular Disease Physician	$470.3K	$0
Nzeadibenma Uzochukwu	IL	Diagnostic Radiology Physician	$84K	$360.8K

Nearby Providers

Other providers in the same ZIP code as Melissa Dillmon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dr. Miniyars Pediatrics, P.C.	GA	Pediatrics Physician	$0	$18.8M
Floyd Physicians, LLC	GA	Neonatal-Perinatal Medicine Physician	$0	$2.6M
Ear,nose,& Throat Of Northwest Georgia	GA	Otolaryngology Physician	$0	$2M
Amtran Medical Transport Inc	GA	Land Ambulance	$1.8M	$1.7K
Floyd Healthcare Management Inc	GA	Family Medicine Physician	$0	$1.3M
Travis Whitehead	GA	Emergency Medicine Physician	$70.8K	$702.1K
Kathrine Whitehead	GA	Emergency Medicine Physician	$59.8K	$626.1K
Surgery Center Of Rome, LP	GA	Ambulatory Surgical Clinic/Center	$681.8K	$0
Jason Smith	GA	Procedural Dermatology Physician	$445K	$0
Scott Mcdaniel	GA	Professional Counselor	$0	$423.4K

Melissa Dillmon — Billing Profile & Reimbursement Data

Sign up for Melissa Dillmon — Billing Profile & Reimbursement Data policy alerts

Melissa Dillmon — Billing Profile & Reimbursement Data

Sign up for Melissa Dillmon — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References